China Strategy Tracker

AI narrative under scrutiny – time to rebalance

Equity Strategy
China

- Muted market turnover suggests better returns in defensive sectors and pressure on the AI-heavy info tech sector…
- …further catalysts and recovery in daily turnover to above RMB2trn needed for the AI trade to bounce back
- 10 stocks, four themes: AI, high-quality dividends, beneficiaries of the six networks, and biotech going global

Jeffrey Xie* (Reg. No. S1700523100002)
Analyst, China Equity Strategy Research
HSBC Qianhai Securities Limited
jeffrey.p.xie@hsbcqh.com.cn
+86 10 5795 2361

Neal Chen*, PhD (Reg. No. S1700524120001)
Analyst, China Equity Strategy Research
HSBC Qianhai Securities Limited
neal.m.chen@hsbcqh.com.cn
+86 21 5066 2066

Steven Sun*, CFA (Reg. No. S1700517110003)
Head of Research, HSBC Qianhai Securities Limited
HSBC Qianhai Securities Limited
stevensun@hsbcqh.com.cn
+86 755 8898 3158

Lydia Li*, CFA (Reg. No. S1700525040002)
Analyst, China Equity Strategy Research
HSBC Qianhai Securities Limited
lydia.j.y.li@hsbcqh.com.cn
+86 21 5066 2022

** Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is not registered/ qualified pursuant to FINRA regulations.*

Defensive sectors outperform. As A-share daily turnover trends lower to cRMB1.5trn, market risk appetite has diminished and defensive sectors have been outperforming the overall market. In our 4Q26 outlook (see *China Equity Strategy - 4Q26 outlook: Reality check*, 13 October 2026), we concluded defensive sectors like financials and healthcare show more resilience amid sluggish market turnover, whereas a sustained comeback in the AI-heavy info tech sector normally materialises when turnover is above RMB2.0trn. Recent market movements validate our view, and the slight beat in September economic data (retail sales up 1.1% y-o-y, and FAI y-o-y decline narrowed to 7.2%) also lent support to non-tech sectors such as consumers and financials. For the AI trade, we retain a positive long-term view. That said, a list of negatives (e.g., Anthropic's IPO valuation markdown, CPO paradigm switch, and Elice Group's IPO debut sell-off) weigh on short-term sentiment. Further catalysts and a recovery in market turnover are the key factors to watch.

Data highlights: 1) Since September, margin financing accounts have had net outflows of RMB178.6bn, of which the IT sector contributed RMB90.1bn. **2)** Weekly AI token usage on OpenRouter rose to 164trn in the week ending 16 October, up 20% vs September's average, with Chinese models accounting for 82% of the top nine large language models' (LLMs) token usage. **3)** Global semi sales grew 144% y-o-y in August, while Taiwan's outsourced semiconductor assembly and test (OSAT) sales were up 42% y-o-y in September, both accelerating from prior ones. **4)** DRAM and NAND flash wafer prices have increased 12% and 9% respectively since September. **5)** Secondary home prices in tier-1 cities rose 0.2% m-o-m in September, the seventh consecutive sequential increase and accelerating from the 0.1% m-o-m growth in August.

Tighter global liquidity: The latest US inflation numbers (CPI up 3.7% y-o-y in September) suggest more rate hikes may be needed to bring inflation back to the Fed's target range (see *US CPI (Sep): Small upside surprise*, Ryan Wang, 14 October 2026). While Federal Fund Futures (FFF) imply no rate hike in October, they point to three 25bp hikes by end-2027, which could keep global liquidity tight and hinder the rotation from DM to EM.

10 stocks, four investment themes based on our analysts' bottom-up analysis: 1) AI: **Naura Tech, Shengyi Tech,** and **Kingdee**; 2) high-quality dividends: **Midea, Bank of Chengdu** and **Guangdong Expressway**; 3) beneficiaries of the six networks: **Nari Tech** and **Sieyuan Electric**; and 4) biotech going global: **Wuxi Bio** and **Hansoh Pharma**.

Less bull, more bite
The 25th edition of the EM Sentiment Survey
Click to view

Disclosures & Disclaimer
This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it.

Issuer of report: HSBC Qianhai Securities Limited

View HSBC Qianhai Securities at:
https://www.research.hsbc.com

Contents

Index targets, sector allocations, stock ideas, and sector views	3
Market focus	5
Macro focus	7
Liquidity focus	8
Sectors: Growth sectors	10
Sectors: Value sectors	12
Global markets	14
Sino-US links	15
Valuation and risks	16
Disclosure appendix	**18**
Disclaimer	**21**

Index targets, sector allocations, stock ideas, and sector views

Exhibit 1. HSBC Qianhai end-2026e index targets

	SHCOMP	CSI 300	SZCOMP
Dividend yield (%)	3.0	2.8	2.2
Index level	3,716.3	4,170.6	11,802.5
EPS growth YR1 (2026e)	25.3%	16.3%	43.4%
EPS growth YR2 (2027e)	12.4%	18.3%	31.9%
Growth in stage 2	10.0%	11.0%	13.0%
Number of years of excess growth	10	10	10
Perpetual growth rate (%)	3.7	3.4	3.9
COE (%)	9.00	9.00	9.00
Payout ratio (%)	39.8	38.4	41.9
Fair value	4,109	4,924	14,878
Undervalued/overvalued vs fair value	-10%	-15%	-21%
HSBC Qianhai's end-2026e targets	**4,100**	**4,800**	**14,500**
Target implied forward PE (x)	14.7	15.5	23.2
Index upside	**10.3%**	**15.1%**	**22.9%**

Note: Index upside calculated based on index levels as of 16 October 2026.
Source: Bloomberg consensus estimates, HSBC Qianhai Securities estimates

Exhibit 2. Sector allocations

Sector	Benchmark weight	Sector weighting	Growth vs average (2027e)	3M earnings revision (2027e)	3M PE re-rating (2027e)	Investor sentiment	2026 y-t-d performance
Info Tech	22.5%	Overweight	Higher	Positive	Downward	Negative	+0.8%
Healthcare	6.0%	Overweight	Lower	Positive	Downward	Negative	-8.0%
Materials	11.8%	Neutral	Higher	Positive	Downward	Negative	-12.4%
Utilities	3.9%	Neutral	Lower	Negative	Upward	Negative	+3.3%
Comm Svs	2.4%	Neutral	Lower	Negative	Upward	Positive	-14.3%
Energy	5.6%	Neutral	Lower	Positive	Upward	Positive	+14.6%
Financials	17.4%	Neutral	Lower	Positive	Upward	Positive	-5.9%
Cons Stap	5.3%	Neutral	Higher	Negative	Upward	Positive	-12.3%
Industrials	17.8%	Underweight	Higher	Positive	Downward	Negative	-18.7%
Cons Disc	6.4%	Underweight	Higher	Negative	Upward	Negative	-20.8%
Real Estate	0.9%	Underweight	Lower	Negative	Upward	Positive	-14.4%

Note: Data updated to 16 October 2026.
Source: Wind, Wind consensus estimates, HSBC Qianhai Securities estimates

Exhibit 3. HSBC Qianhai Securities' key stock ideas

Theme	Ticker	Company	Industry	Rating	TP	Curr price	Upside	Mcap	3M ADT	PE (x)	EPSg (%)	PB (x)	ROE (%)	DY (%)	Analyst*
					LC	LC		USDbn	USDm	2027e	2027e	2027e	2027e	2027e	
AI	002371 CH	NAURA	Electronics	Buy	1031.90	593.63	74%	64.6	912.3	44.3	39.4	8.1	20.0	0.2	Cara Su
	600183 CH	SYTECH	Electronics	Buy	191.50	114.60	67%	41.6	1370.2	25.1	47.2	14.4	59.9	3.4	Cara Su
	268 HK	KINGDEE INT'L	Computer	Buy	16.00	8.37	91%	4.4	56.8	36.5	76.8	3.2	8.3	0.1	Yiran Liu
High dividend	000333 CH	MIDEA GROUP	Home App	Buy	97.00	84.60	15%	96.1	347.1	13.3	21.4	2.5	19.7	5.8	Li Quan
	601838 CH	BANK OF CHENGDU	Banks	Buy	24.40	19.09	28%	12.1	57.5	5.6	4.5	0.8	14.0	5.5	Angel Sun
	000429 CH	GD EXPRESSWAY	Transportation	Buy	15.50	13.66	13%	4.0	18.7	18.1	-0.6	2.4	13.3	3.9	William Sun
"Six networks"	600406 CH	NARI-TECH	Elec Equip	Buy	36.20	22.73	59%	27.3	167.0	17.4	14.7	3.0	17.7	3.4	Corey Chan
	002028 CH	SIEYUAN	Elec Equip	Buy	266.00	118.03	125%	13.8	251.3	16.3	38.8	3.9	26.3	1.1	Dun Wang
Biotech going global	2269 HK	WUXI BIO	Healthcare	Buy	64.60	48.20	34%	25.3	215.8	21.6	18.8	3.3	14.0	0.0	Linda Shu
	3692 HK	HANSOH PHARMA	Healthcare	Buy	49.50	31.74	56%	24.5	44.1	23.6	2.0	4.3	16.9	1.7	Linda Shu

Note: Priced as of 16 October 2026. *Employed by a non-US affiliate of HSBC Securities (USA) Inc. and not registered/qualified pursuant to FINRA regulations.
Source: Wind, Bloomberg, HSBC Qianhai Securities estimates

Exhibit 4. Key sector views

Sector	Key views	Links	Most liquid stocks over L1M
Info Tech (Overweight)	**Optical transceivers**: Potential FCC restrictions' near-term valuation pressure is likely to outweigh earnings impact; a blanket restriction would face significant practical constraints. **Software**: DeepSeek's latest model significantly improves agentic coding with unchanged pricing, implying further token deflation; intense competition increases LLM monetisation uncertainty; applications stand to benefit from lower token cost.	*China Technology - Optical transceivers: Assessing potential FCC policy implications*, Bingyi Zheng, 5 August 2026 *China Software - Deepseek v4.1 flash updated version underscores continued token deflation trend*, Yiran Liu, 19 October 2026	Innolight (300308 CH) Eoptolink (300502 CH) CXMT (688825 CH)
Healthcare (Overweight)	**Is**: 2H26-2027e outlook: stabilised China growth, accelerating global footprint. **CXOs**: We favour companies with strong growth momentum backed by new products. **AIDD**: We expect a more volatile 4Q26, while China's faster execution and asset-backed monetisation offers a differentiated investment opportunity.	*China Pharmaceutical - China business under pressure; global pipeline progress turns next narrative focus*, Linda Shu, 28 September 2026 *China CXOs - How to position in 2027: Conviction buy with strong growth momentum backed by new products*, Linda Shu, 21 September 2026 *China Healthcare - AIDD and AI4S update: Market volatility and China opportunity*, Linda Shu, 16 October 2026	Wuxi Apptec (603259 CH) HPGC (600664 CH) Hengrui Pharma (600276 CH)
Materials (Neutral)	**Chemicals**: We expect the refining value chain to lead sequential growth in 3Q, but record freight costs could weigh on 4Q earnings; if the Middle East conflict ends, we would prefer phosphate producers into 2027. **Copper**: Solid production, cost control and clearer shareholder returns to narrow valuation discount vs global peers.	*China Chemicals - 3Q26 preview: Refining to lead 3Q growth, freight pressure to rise in 4Q*, Yi Ru, 13 October 2026 *China Copper Sector - Price breakout and solid execution to drive valuation catch-up*, Stephen Wang, 15 September 2026	China Jushi (600176 CH) Zijin Mining (601899 CH) Sinocera (300285 CH)
Utilities (Neutral)	**Power utilities:** Power prices could rebound with the rally in coal prices and boost power utility earnings in 2027e.	*China Power Utilities - Turning a lot more bullish*, Daniel Yang, 9 October 2026	Yangtze Power (600900 CH) MD Electric (000993 CH) HD LN Energy (600396 CH)
Comm Svs (Neutral)	**Telcos**: We expect less intense mobile competition in 2H26 and one-offs could support a modest recovery in net profits. **Gaming**: Recent company visits suggest that gaming companies are constructive about overseas markets − particularly SLG and casual games − and that AI adoption is deepening in-game development. **Video**: AI model upgrades should help boost AI video content; AI will significantly reduce content costs and increase gross margins.	*China Telcos - Modest recovery in 2H26*, Piyush Choudhary, 23 September 2026 *China Gaming - Company visit takeaways*, Jing Han, 18 September 2026 *China Video Industry - Industry revolution on AI video breakthroughs*, Jing Han, 15 October 2026	Bluefocus (300058 CH) Mango (300413 CH) Kunlun (300418 CH)
Energy (Neutral)	**Oil & gas**: HSBC Global Investment Research raised Brent forecast to USD90/b for 2026 and USD85/b for 2027, on Hormuz disruptions being the new normal. **Coal**: Suspended production in Shanxi has lasted longer than expected; output contraction likely to linger into 3Q.	*Oil markets - Raising forecasts on disrupted Hormuz new normal*, Kim Fustier, 8 September 2026 *China coal - Stringent production inspections to linger through 3Q26*, Daniel Yang, 14 August 2026	Jereh Group (002353 CH) PetroChina (601857 CH) China Shenhua (601088 CH)
Financials (Neutral)	**Banks:** Capital injections plan announced on 6 September 2026 could help: 1) improve banks' asset growth; 2) accelerate earnings growth; and 3) increase banks' dividend payout ratio.	*China Banks - Capital injection: Second batch confirmed*, Gary Lam, 7 September 2026	Ping An Ins (601318 CH) Eastmoney (300059 CH) CMB (600036 CH)
Cons Stap (Neutral)	**Baijiu:** Sell-through was down by c10% during the Mid-autumn Festival and National Day holiday, which indicates that an industry recovery may need more time. Market consolidation continues. **Dairy**: Raw milk prices are rising, easing the industry price competition, which is positive for dairy product leaders. **Snacks**: We are positive on the snack retailer sector which could continue to see high growth. **Hog industry:** We remain constructive on the hog price upcycle in 2027 and prefer players with leading cost advantages.	*China Consumer - Golden week holiday: Largely in line*, Kathy Song, 8 October 2026 *China Consumer Tracker - September retail sales showed marginal improvement* , Kathy Song, 20 October 2026 *China's hog industry - Capacity reduction accelerated in August*, Yihui Sha, 17 September 2026	Moutai (600519 CH) Jinjian Cereals (600127 CH) LHG (600186 CH)
Industrials (Underweight)	**Power equipment**: The market size for solid-state transformers (SST), solid-state circuit breakers (SSCB) and battery backup units (BBU), will reach RMB84.9bn (240% 2027-30 CAGR), RMB14.9bn (211% 2027-30 CAGR) and RMB9.1bn (11% 2026-30 CAGR), respectively, in AIDCs by 2030. **Humanoid robots:** Based on the existing price quotes of key components, the BOM of a wheeled humanoid robot with grippers could be as low as cRMB100k/unit, which implies a payback period of just two years. **Battery equipment**: New orders for lithium battery equipment could reach 622-809GWh during 2026-28e.	*China Power Equipment - Better visibility for 800VDC benefits supply chain players*, Corey Chan, 29 September 2026 *China Industrials - Trip takeaways: Humanoid robot progress ahead of track*, Corey Chan, 11 September 2026 *China Battery Equipment - Is the boom over?*, Corey Chan, 5 August 2026	CATL (300750 CH) CSSC (600150 CH) DHI (002487 CH)
Cons Disc (Underweight)	**Auto**: HSBC Global Investment Research cut 2026e PV demand growth forecast to -20% (from -13%), and EVs to -10% (from -6%) due to weak domestic demand. **Home appliances:** The industry was under pressure in 2Q26, while overseas sales were resilient. We expect industry earnings growth to bottom out in 3Q26e.	*China EV Tracker - Demand recovery remains elusive*, Yuqian Ding, 20 October 2026 *China Home Appliances - 1H26 results preview: Earnings bottoming out*, Li Quan, 16 July 2026	JAC (600418 CH) Midea (000333 CH) BYD (002594 CH)
Real Estate (Underweight)	**Property:** Broad inventory will decline at an 11-13% CAGR in 2025-30e, and the supply squeeze coinciding with improved resale liquidity could support primary sell-through and pricing.	*China Real Estate - Back from holidays, back to fundamentals*, Michelle Kwok, 8 October 2026	VANKE (000002 CH) 5I5J (000560 CH) Poly Develps (600048 CH)

Source: Wind, HSBC Global Investment Research, HSBC Qianhai Securities estimates

Market focus

Exhibit 5. Key events to watch

Corporate earnings

Date	Event	Key data to watch	Consensus (USDbn)	Implications
21 Oct	Meta FY3Q26 earning	CY27 capex	202	Overseas compute value chain
28 Oct	Alphabet FY3Q26 earnings	CY27 capex	313	Overseas compute value chain
28 Oct	Microsoft FY1Q27 earnings	CY27 capex	206	Overseas compute value chain
29 Oct	Amazon FY3Q26 earnings	CY27 capex	285	Overseas compute value chain

Macro data release

Date	Event	Market expectations	Previous	Implications
29 Oct	FOMC Rate Decision	3.75%-4.00%	3.75%-4.00%	Rates, liquidity and valuation
06 Nov	US nonfarm payrolls for Oct	N.A	29,000	Rates, liquidity and valuation
10 Nov	US CPI for Oct	N.A	+0.6% m-o-m; +3.7% y-o-y	Rates, liquidity and valuation
10 Nov	US core CPI for Oct	N.A	+0.3% m-o-m; +2.6% y-o-y	Rates, liquidity and valuation

Source: Company data, BBG consensus estimates, HSBC Qianhai Securities


Exhibit 6. Valuation levels of broad-based indices and industries

Index	PE-TTM	Percentile	Median	Historical range	PB-LF	Percentile	Median	Historical range
All A-shares	20.0x	56.8	19.3x	[11.5, 58.2]	1.7x	30.3	1.9x	[1.3, 7.4]
SSE50	10.8x	47.9	10.9x	[6.9, 48.5]	1.2x	32.2	1.4x	[1.0, 7.2]
CSI100	11.4x	47.6	11.6x	[7.1, 50.1]	1.2x	21.2	1.4x	[1.0, 7.3]
CSI300	13.0x	46.3	13.2x	[8.0, 50.7]	1.4x	20.1	1.6x	[1.1, 7.5]
CSI500	29.2x	46.6	30.0x	[15.6, 92.8]	2.1x	37.5	2.3x	[1.4, 5.9]

Industry	PE-TTM	Percentile	Median	Historical range	PB-LF	Percentile	Median	Historical range
Basic Chem	23.7x	40.9	25.5x	[12.5, 76.6]	2.0x	23.5	2.4x	[1.4, 6.8]
Steel	29.4x	71.3	21.1x	[4.7, 153.7]	1.0x	20.5	1.2x	[0.7, 4.7]
NF Metals	15.5x	8.1	34.3x	[12.5, 140.3]	2.6x	35.9	3.0x	[1.4, 13.7]
Blg Materials	34.4x	73.7	24.9x	[10.0, 124.6]	1.4x	11.8	2.0x	[0.9, 6.7]
Construction	14.2x	50.3	14.1x	[7.1, 92.8]	0.7x	1.6	1.5x	[0.6, 7.0]
Elec Equip	25.4x	13.4	37.6x	[13.6, 100.0]	2.4x	23.7	3.3x	[1.5, 9.8]
Machinery	37.0x	72.8	29.7x	[11.8, 136.1]	2.8x	56.7	2.6x	[1.4, 8.9]
Defense	55.5x	38.9	60.4x	[17.8, 245.8]	3.0x	38.2	3.3x	[1.2, 12.7]
Auto	23.8x	57.7	21.8x	[7.9, 70.0]	2.0x	32.4	2.3x	[1.1, 6.2]
Home App	14.6x	29.3	16.6x	[10.6, 89.5]	2.2x	23.0	2.7x	[1.0, 5.3]
Textile	24.2x	38.7	26.0x	[13.1, 98.3]	1.7x	18.1	1.9x	[1.1, 6.3]
Light Mfg	32.2x	54.2	30.9x	[14.0, 113.3]	1.7x	23.6	2.1x	[1.1, 6.4]
Retail	31.8x	53.6	30.2x	[13.1, 96.2]	1.6x	16.6	2.2x	[1.2, 8.6]
Agriculture	79.2x	87.7	42.5x	[15.0, 157.0]	2.4x	14.0	3.3x	[1.1, 8.1]
F&B	21.1x	15.8	30.5x	[16.5, 101.0]	3.4x	9.5	5.2x	[2.0, 12.7]
Social Svs	39.9x	30.5	47.0x	[17.4, 209.7]	2.4x	6.4	3.6x	[1.6, 10.5]
Healthcare	31.4x	26.6	36.7x	[20.3, 99.4]	2.5x	12.6	4.0x	[1.6, 8.4]
Utilities	21.6x	45.6	22.5x	[13.8, 74.4]	1.6x	19.2	1.9x	[1.3, 5.3]
Transportation	16.7x	38.4	18.2x	[10.0, 58.6]	1.2x	1.9	1.6x	[1.1, 6.6]
Real Estate	13.3x	29.8	17.5x	[6.8, 120.0]	0.8x	9.6	1.8x	[0.5, 10.1]
Electronics	50.5x	55.5	47.7x	[20.3, 118.1]	5.2x	94.3	3.4x	[1.3, 9.0]
Computer	56.9x	59.2	52.9x	[18.6, 159.7]	3.3x	29.6	3.9x	[1.9, 15.8]
Media	34.6x	23.2	44.1x	[19.5, 141.8]	2.6x	25.2	3.2x	[1.6, 11.5]
Communications	41.5x	62.9	38.1x	[9.2, 96.3]	4.8x	94.8	2.5x	[0.7, 8.5]
Banks	6.5x	40.5	6.8x	[4.3, 65.3]	0.5x	15.5	1.0x	[0.4, 8.1]
Non-bank Fin	8.8x	0.0	17.6x	[8.8, 174.0]	1.0x	2.9	2.0x	[0.9, 14.3]
Conglomerates	73.7x	83.8	47.9x	[20.7, 176.7]	2.5x	48.1	2.5x	[0.9, 7.9]
Coal	18.8x	67.5	13.1x	[5.7, 67.5]	1.6x	51.8	1.5x	[0.8, 11.1]
Oil & Gas	16.6x	39.8	18.6x	[9.0, 46.8]	1.4x	24.5	1.8x	[1.1, 8.1]
Env Prot	23.4x	28.4	30.0x	[14.7, 89.5]	1.5x	7.8	2.5x	[1.1, 8.3]
Beauty Care	28.2x	11.4	38.2x	[11.8, 164.1]	2.4x	14.1	3.7x	[0.8, 7.2]


Note: Data updated to 16 October 2026. Grey font implies PE multiples of cyclical sectors, which may be less relevant. Historical range dates back to the start of 2005.
Source: Wind, HSBC Qianhai Securities

Exhibit 7. China's market is trading at a 21.8% discount vs EM (10.1x forward PE for FTSE China vs 13.0x forward PE for FTSE EM)




Note: Data updated to 16 October 2026.
Source: FTSE Russell, FactSet, HSBC Qianhai Securities

Exhibit 8. During L1M, electronics and communications saw the most upward earnings revisions; steel and construction were revised down the most




Note: Data updated to 16 October 2026.
Source: Wind, HSBC Qianhai Securities

Exhibit 9. Consensus 2027e earnings for IT and healthcare have seen upward revisions of 11.8% and 1.8%, respectively, since 2H26



Note: Data updated to 16 October 2026. The real estate sector, whose estimated 2027e net loss narrowed from -RMB6.7bn to -RMB4.7bn, is excluded from the chart.
Source: Wind consensus, HSBC Qianhai Securities


Exhibit 10. Consensus 2027e earnings for STAR50 have seen upward revisions of 9.7%, while HSTECH saw downward revisions of 5.7% since 2H26



Note: Data updated to 16 October 2026.
Source: Wind consensus, HSBC Qianhai Securities


Macro focus

Exhibit 11. In September 2026, major economic indicators suggest moderate upside surprises…




Note: IP is in real terms, while retail sales and FAI are in nominal terms.
Source: Bloomberg consensus, HSBC estimates, HSBC Qianhai Securities

Exhibit 12. …and within FAI, manufacturing and infra investment saw narrower y-o-y decline…




Source: Wind, HSBC Qianhai Securities

Exhibit 13. …the y-o-y growth of M1 (+3.2%), M2 (+7.1%), total social financing (+7.2%) all decelerated…




Source: Wind, HSBC Qianhai Securities

Exhibit 14. …PMI of manufacturing edged up to 50.1, while that of high-tech manufacturing edged down to 52.5…




Source: Wind, HSBC Qianhai Securities

Exhibit 15. …CPI rose to 0.9% y-o-y and PPI picked up to 5.0% y-o-y, due to higher energy prices



Source: Wind, HSBC Qianhai Securities


Exhibit 16. Residential house sales recovery slowed recently



Source: Wind, HSBC Qianhai Securities


Liquidity focus

Exhibit 17. Market turnover dropped further in October 2026, with the 10-day moving average turnover cRMB1.6trn




Source: Wind, HSBC Qianhai Securities

Exhibit 18. New mutual fund issuances recovered further, up 9% y-o-y, y-t-d




Note: Data updated to 16 October 2026.
Source: Wind, HSBC Qianhai Securities

Exhibit 19. ETFs have seen net inflows of RMB412.1bn since July 2026




Note: Data updated to 16 October 2026.
Source: Wind, HSBC Qianhai Securities

Exhibit 20. The margin financing balance dropped to RMB2.4trn in October 2026




Source: Wind, HSBC Qianhai Securities

Exhibit 21. Since September 2026, IT had the highest net outflows through the margin financing account…




Note: Data updated to 16 October 2026.
Source: Wind, HSBC Qianhai Securities

Exhibit 22. …and at the stock level, margin financing mainly sold Innolight, CXMT and Eoptolink




Note: Data updated to 16 October 2026.
Source: Wind, HSBC Qianhai Securities

Exhibit 23. Mainland China equities have seen outflows from foreign funds since mid-January 2026




Note: Data based on a sample of funds and updated to 16 October 2026.
Source: Morningstar, HSBC Qianhai Securities

Exhibit 24. Southbound Stock Connect has seen net inflows of HKD435.2bn y-t-d




Note: Data updated to 16 October 2026.
Source: Wind, HSBC Qianhai Securities

Exhibit 25. Since September 2026, financials and IT saw the most inflows through the southbound channel…




Note: Data updated to 16 October 2026.
Source: Wind, HSBC Qianhai Securities

Exhibit 26. …and at the stock level, southbound funds bought AIA and Z AI, and sold SMIC



Note: Data updated to 16 October 2026.
Source: Wind, HSBC Qianhai Securities


Exhibit 27. A-share buybacks reached RMB135.1bn y-t-d, up 11% y-o-y, while the Hong Kong market had share buybacks of RMB108.3bn, down 19% y-o-y



Note: Data updated to 16 October 2026.
Source: Wind, HSBC Qianhai Securities


Sectors: Growth sectors

Exhibit 28. AI: Weekly token usage rose to 164trn; Chinese models accounted for 82% of top nine models' token usage




Note: Data updated as of the week ending 16 October 2026.
Source: OpenRouter, HSBC Qianhai Securities

Exhibit 29. AI: Anthropic's ARR reached USD76.8bn in September while OpenAI's ARR was USD50.4bn




Source: Wind, TickerTrends, HSBC Qianhai Securities

Exhibit 30. Semiconductors: The strong growth momentum continues




Source: Wind, HSBC Qianhai Securities

Exhibit 31. Memory: DRAM and NAND Flash wafer prices have increased 12% and 9% respectively since September




Source: Wind, HSBC Qianhai Securities

Exhibit 32. Solar: Cell prices have rebounded slightly




Source: Wind, HSBC Qianhai Securities

Exhibit 33. EV batteries: Prices have continued to rebound




Note: LFP – Lithium iron phosphate. Ternary cell (NCM) – Nickel, Cobalt, and Manganese.
Source: Baiinfo, HSBC Qianhai Securities

Exhibit 34. Gaming: Domestic game licence issuance reached 206 in September 2026




Source: NPPA, HSBC Qianhai Securities

Exhibit 35. Film: Box office revenue was RMB29.6bn in 9M26, down 29% y-o-y and 39% below the 9M19 level




Source: Maoyan, HSBC Qianhai Securities

Exhibit 36. NEV: In September 2026, China NEV penetration went up 9ppt y-o-y to 67%, a record high




Source: CPCA, HSBC Qianhai Securities

Exhibit 37. NEV: The discount rate for NEVs increased slightly to 8.8% in September 2026



Source: CPCA, HSBC Qianhai Securities


Exhibit 38. Home appliances: In September 2026, AC exports grew 8.0% y-o-y while domestic sales fell 24% y-o-y



Note: AC – Air conditioner.
Source: ChinaIOL, HSBC Qianhai Securities


Sectors: Value sectors

Exhibit 39. Property: Monthly sales from the top 100 developer amounted to RMB184.4bn in September 2026, down 27.1% y-o-y




Source: CRIC, HSBC Qianhai Securities

Exhibit 40. Property: Both housing new starts and housing completions declined c25% y-o-y in September 2026




Source: Wind, HSBC Qianhai Securities

Exhibit 41. Property: More cities have seen secondary market home prices stabilise in September 2026




Source: Wind, HSBC Qianhai Securities

Exhibit 42. Banks: Moderately loose monetary policy is set to lower the average loan rate




Source: Wind, HSBC Qianhai Securities

Exhibit 43. Baijiu: Moutai wholesale prices stabilised at cRMB1,700/bottle




Source: Jinrijiujia, HSBC Qianhai Securities

Exhibit 44. Pork: Average wholesale price declined 3.9% since September




Source: Wind, HSBC Qianhai Securities

Exhibit 45. Cement: Countrywide average price rebounded in October 2026




Source: Wind, HSBC Qianhai Securities

Exhibit 46. Steel: The price index was lukewarm in October 2026




Source: Wind, HSBC Qianhai Securities

Exhibit 47. Coal: Prices remained high in October 2026



Source: Wind, HSBC Qianhai Securities


Exhibit 48. Chemicals: Ethylene price remained strong in October 2026



Source: Wind, HSBC Qianhai Securities


Global markets

Exhibit 49. CPI: Global inflation remained sticky in September 2026, but rising oil prices could lead to more uncertainty




Source: Wind, HSBC Qianhai Securities

Exhibit 50. CPI: Rising oil price still an upside risk to US inflation




Source: Wind, HSBC Qianhai Securities

Exhibit 51. The US unemployment rate rose slightly, and payroll employment was below consensus




Source: Wind, HSBC Qianhai Securities

Exhibit 52. US Treasury yields rose further in October 2026




Source: Wind, HSBC Qianhai Securities

Exhibit 53. Oil has outperformed other asset classes since September 2026



Note: Performance refers to price return in USD, which does not include dividends.
Source: Wind, HSBC Qianhai Securities


Exhibit 54. Taiwan, the US, and Japan stock markets have been more resilient since September 2026



Note: Performance refers to price return in USD, which does not include dividends.
Source: Wind, HSBC Qianhai Securities


Sino-US links

Exhibit 55. In August 2026, mainland China's UST holdings decreased USD27.3bn m-o-m




Source: Wind, HSBC Qianhai Securities

Exhibit 56. In October 2026, mainland China-US flights were only at 28.7% of the level in 2019




Note: Data updated to the week ending on 18 October 2026.
Source: DAST, HSBC Qianhai Securities

Exhibit 57. Mainland China-US flights are scheduled to recover in a phased manner




Source: DAST, Ministry of Foreign Affairs, HSBC Qianhai Securities

Exhibit 58. Share of mainland China's exports: US stabilised, while EU declined recently



Note: ME – Middle East.
Source: General Administration of Customs, HSBC Qianhai Securities

Exhibit 59. Share of US imports: Mainland China bottomed, while East Asia ex MC and SA & SEA increased



Note: MC – Mainland China. SA – South Asia. SEA – Southeast Asia.
Source: US Census Bureau, HSBC Qianhai Securities

Valuation and risks

		Valuation	Risks
NAURA Tech 002371 CH **Buy**	Current price: **RMB593.63** Target price: **RMB1,031.90** Upside: **74%**	**Investment rationale:** We believe NAURA Technology is well positioned to gain market share with its fast-growing product coverage and will benefit from localisation. **Valuation:** We value the stock using a PS multiple. We forecast a 2026-28 revenue CAGR of 27%, roughly in line with its global peers' average revenue CAGR of 26%. We value the stock at a 11.7x PS multiple (in line with its global peers' average). Against our 2027 revenue per share estimate of RMB88.2, we derive our TP of RMB1,031.90. Our TP implies c74% upside from current levels; accordingly, we have a Buy rating on the stock. **Cara Su* (S1700525070001)** | cara.z.h.su@hsbcqh.com.cn | +86 21 50662080	**Key downside risks** • Slowdown in domestic semi equipment capex. • Slower-than-expected progress in new equipment R&D. • Glass substrate design wins below expectation.
Shengyi Technology 600183 CH **Buy**	Current price: **RMB114.60** Target price: **RMB191.50** Upside: **67%**	**Investment rationale**: We believe Shengyi Technology is a key beneficiary of continued AI infrastructure build-out, backed by strong capacity execution and supply chain management. **Valuation**: We use a target PE multiple to value the stock. We estimate a 2026-28 EPS CAGR of 41%, above the mid-cycle 2016-21 EPS CAGR of 19%. We use 2016-21 as our reference period since it is the previous PCB upcycle, as we believe Shengyi's near-term operation situation will be similar. Compared with the mid-cycle average PE multiple of 22x over 2016-21, we use a target PE of 47.8x. Based on our 12-month forward EPS estimate of RMB4.01, we derive our target price of RMB191.50. Our target price implies c67% upside from current levels; accordingly, we have a Buy rating on the stock. **Cara Su* (S1700525070001)** | cara.z.h.su@hsbcqh.com.cn | +86 21 50662080	**Key downside risks** • Slower-than-expected PCB business growth. • Inability to cope with material cost changes. • Intense competition in the industry.
Kingdee 268 HK **Buy**	Current price: **HKD8.37** Target price: **HKD16.00** Upside: **91%**	**Investment rationale:** We believe Kingdee could benefit from the declining token pricing, which could drive a reduction in R&D expenses and margin expansion for AI software applications. **Valuation:** We use a target PS multiple to value the stock. Kingdee's adjusted historical average PS since 2018 is 6.6x (excluding PS multiples larger than the original historical average PS + 1 SD). Kingdee's revenue grew at a CAGR of 14% over 2018-25. We estimate Kingdee's revenue CAGR at 12% over 2025-28e. Hence, we apply a 2027e target PS of 5.6x (12/14*6.6) to value Kingdee. Based on our 2027e revenue of RMB8.7bn, RMB/HKD of 1.16, and 3,586 million shares, we arrive at our TP of HKD16.00, implying c91% upside to the current price; thus we have a Buy rating on the stock. **Yiran Liu* (S1700520040001)** | yiran1.liu@hsbcqh.com.cn | +86 10 5795 2349	**Key downside risks** • Weaker-than-expected macroeconomic data. • More intense competition. • Uncertainty in AI monetisation progress.
Nari Technology 600406 CH **Buy**	Current price: **RMB22.73** Target price: **RMB36.20** Upside: **59%**	**Investment rationale:** We like Nari Technology as we are positive about the spending outlook for secondary equipment and ultra-high voltage (UHV) projects. **Valuation:** We use a DCF model to value the stock. Our key assumptions include (1) a COE of 9.2%, derived from a risk free rate of 4.25%, a market risk premium of 4.75%, and a beta of 1.05; (2) an after-tax cost of debt of 3%; (3) a debt-to-capital ratio of 2%; (4) operating cash flow to grow at a CAGR of 7% in 2023-37e; (5) capital expenditure: we expect capex of RMB1,800m in 2026e and RMB650-700m per annum in 2027-37e, reflecting steady maintenance capex; and (6) a terminal growth rate at 2.5%. Our TP implies 59% upside from current levels; thus we have a Buy rating on the stock. **Corey Chan* (1700518100001)** | corey.chan@hsbcqh.com.cn | +86 21 5066 2001	**Key downside risks** • Weaker-than-expected investment in power network communication devices. • Lower-than-expected investment in the national grid distribution network. • Significant order delays or cancellations. • Higher-than-expected receivable provisions. • Weaker-than-expected margin due to intense competition.
Sieyuan Electric 002028 CH **Buy**	Current price: **RMB118.03** Target price: **RMB266.00** Upside: **125%**	**Investment rationale:** We expect Sieyuan Electric to benefit from the rising power-supply side demand in the development of new-type power grids and computing power networks. **Valuation:** We use a DCF model to value the stock. Our key assumptions include: 1) cost of equity (COE): We use a COE of 9.2%. This is derived from a risk-free rate of 4.25%, a market risk premium of 4.75%, and a beta of 1.05. 2) Cost of debt (COD): We assume a pre-tax cost of debt of 5.0% and an after-tax cost of debt of 4.3%. We use our 2026e debt-to-capital ratio of 0.6% as our long-term debt-to-capital ratio. 3) Operating cash flow: We assume an operating cash flow CAGR (before changes in the working capital) of 18.7% in 2025-38e.4) Capital expenditure: We estimate capex of RMB892m in 2026e, gradually increasing to RMB3,530m in 2038e. 5) Terminal growth rate of 2%: We assume the company will reach a steady growth period after 2038e. Our target price of RMB266.00 implies c125% upside; thus we have a Buy rating on the stock. **Dun Wang*, CFA, CPA (S1700519060002)** | dun.wang@hsbcqh.com.cn | +86 21 5066 2027	**Key downside risks** • Weaker-than-expected power distribution network investment. • Stronger-than-expected raw material cost inflation. • Weaker-than-expected UHV investment. • Weaker-than-expected renewable investment. • Uncertainty in conducting overseas business. • Smaller-than-expected supply shortages.

		Valuation	Risks
Midea Group 000333 CH/ 300 HK **Buy/Buy**	Current price: **RMB84.60/ HKD93.95** Target price: **RMB97.00/ HKD113.00** Upside: **15%/20%**	**Investment rationale**: We like Midea for its attractive shareholder returns and it is a key beneficiary of the consumer goods trade-in program. **Valuation**: We use a DCF model to value the stock. Our key assumptions include a perpetual growth rate of 2% and a WACC of 8.3% (based on a risk-free rate of 4.25% and a market risk premium of 4.75%). Accordingly, we derive our A-share TP of RMB97.00. We apply a 0% H-A discount and, based on a RMB-HKD exchange rate of 1.17, we arrive at a H-share TP of HKD113. Our A/H share TPs imply c15%/c20% upside from the current A/H-share prices. We believe Midea is able to navigate external uncertainty, and therefore we have Buy/Buy ratings on Midea A/H-shares. **Li Quan* (S1700520030002)** | li.quan@hsbcqh.com.cn | +86 755 8898 3471	**Key downside risks** • Weaker-than-expected policy impact on boosting household appliance sales. • Rising raw material costs. • Adverse exchange rate fluctuations. • Trade friction and tariff barriers. • Competition. • Weaker-than-expected overseas market expansion.
BoCD 601838 CH **Buy**	Current price: **RMB19.09** Target price: **RMB24.40** Upside: **28%**	**Investment rationale:** We like Bank of Chengdu as it has a high dividend yield and stable asset quality. **Valuation:** We use a Gordon growth model (GGM) with a trading discount (TD) to value the stock and derive a target price of RMB24.40. The key assumptions in the valuation model include: (1) a COE of 8.4%, based on a risk-free rate assumption of 4.25%, a market risk premium of 4.75%, and a beta coefficient of 0.86; (2) a terminal growth rate of 2%; (3) a five-year average ROE of 13.6% in 2026-30e; and (4) a trading discount of 40%. Our target price implies c28% upside from current levels. We have a Buy rating on the stock due to its relatively high dividend yield and attractive valuation among A-share banks. **Angel Sun* (S1700519080001)** | angel.y.sun@hsbcqh.com.cn | +86 21 5066 2015	**Key downside risks** • Greater-than-expected decline in asset prices of government-related business. • Asset deterioration in the government sector. • Higher NPL ratio of retail loans.
Guangdong Expressway 000429 CH **Buy**	Current price: **RMB13.66** Target price: **RMB15.50** Upside: **13%**	**Investment rationale:** We like Guangdong Expressway for its leading ROE among domestic peers, an attractive yield profile and potential upside from toll-road reform. **Valuation:** We use a two-stage DCF model to value the stock, with a valuation base year of 2026, 2026-55 FCF estimates for stage I and a perpetual growth rate of 1% for stage II. We use a WACC of 5.0% (based on a risk-free rate of 4.25%, a market risk premium of 4.75%, a beta coefficient of 0.55 and a cost of debt of 3.0%). We derive a target price of RMB15.50, implying 13% upside from the current share price. We have a Buy rating on the stock due to its attractive yield profile. **William Sun*, CFA (S1700522110001)** | william.x.d.sun@hsbcqh.com.cn | +86 21 5066 2061	**Key downside risks** • Greater-than-expected diversion effect from new expressways. • Slower-than-expected progress in expansion projects. • Lower-than-expected tolls.
Wuxi Biologics 2269 HK **Buy**	Current price: **HKD48.20** Target price: **HKD64.60** Upside: **34%**	**Investment rationale:** We favour WuXi Bio, as an industry leader in the CDMO space. **Valuation:** We use a DCF model to value the stock. Our key assumptions include a WACC of 9.0%, derived from a risk-free rate of 4.25%, a market risk premium of 4.25%, a beta of 1.42, and an after-tax cost of debt of 5.3%, and a terminal growth rate of 3.5%, and RMB-HKD forex assumption of 1.16. Our target price of HKD64.60 implies 34% upside from current level; we have a Buy rating on the stock as we are positive on the company's growth prospects and margin profile. **Linda Shu*, PhD (S1700522120001)** | linda.y.l.shu@hsbcqh.com.cn | +86 755 88983246	**Key downside risks** • Progress of potential US legislation to restrict US pharmaceutical companies to contract with WuXi Biologics. • A larger-than-expected impact from US tariffs. • A longer-than-expected period of high US interest rates that constrains the financing capability and project outsourcing demand of biotechnology companies. • Overbuilt capacity for WuXi Bio, with demand shrinking among US and European customers. • Regulatory tightening.
Hansoh 3692 HK **Buy**	Current price: **HKD31.74** Target price: **HKD49.50** Upside: **56%**	**Investment rationale:** We like Hansoh for its rapid growth in domestic sales and continued BD revenue booking with multiple assets set to enter global phase III trials. **Valuation:** We use a DCF model to value the stock. Our key assumptions include a WACC of 8.0%, derived from a risk-free rate of 4.25%, an equity risk premium of 4.75%, a 10-year monthly beta to the HSI of 0.79, a terminal growth rate of 4.0% and an RMB-HKD exchange rate of 1.17. Our DCF-based target price of HKD49.50 implies c56% upside from the current share price; accordingly, we have a Buy rating on the stock. **Linda Shu*, PhD (S1700522120001)** | linda.y.l.shu@hsbcqh.com.cn | +86 755 88983246	**Key downside risks** • Slower-than-expected sales ramp-up of new drugs. • Slower-than-expected R&D progress in key pipeline assets. • Larger-than-expected anti-graft policy impact on innovative drugs' sales ramp-up. • Delays in business development progress.

Note: Priced as of 16 October 2026. *Employed by a non-US affiliate of HSBC Securities (USA) Inc. and not registered/qualified pursuant to FINRA regulations. All the analysts in this table are employed by HSBC Qianhai Securities.
Source: Wind, HSBC Qianhai Securities estimates

Disclosure appendix

Analyst Certification

The following analyst(s), economist(s), or strategist(s) who is(are) primarily responsible for this report, including any analyst(s) whose name(s) appear(s) as author of an individual section or sections of the report and any analyst(s) named as the covering analyst(s) of a subsidiary company in a sum-of-the-parts valuation certifies(y) that the opinion(s) on the subject security(ies) or issuer(s), any views or forecasts expressed in the section(s) of which such individual(s) is(are) named as author(s), and any other views or forecasts expressed herein, including any views expressed on the back page of the research report, accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Jeffrey Xie, Neal Chen, PhD, Steven Sun, CFA, Lydia Li, CFA, Cara Su, Yiran Liu, Li Quan, Angel Sun, William Sun, CFA, Corey Chan, Dun Wang, CFA, CPA and Linda Shu, PhD

Important disclosures

Equities: Stock ratings and basis for financial analysis

HSBC and its affiliates, including the issuer of this report ("HSBC") believes an investor's decision to buy or sell a stock should depend on individual circumstances such as the investor's existing holdings, risk tolerance and other considerations and that investors utilise various disciplines and investment horizons when making investment decisions. Ratings should not be used or relied on in isolation as investment advice. Different securities firms use a variety of ratings terms as well as different rating systems to describe their recommendations and therefore investors should carefully read the definitions of the ratings used in each research report. Further, investors should carefully read the entire research report and not infer its contents from the rating because research reports contain more complete information concerning the analysts' views and the basis for the rating.

HSBC assigns ratings on the following basis:

The target price is based on the analyst's assessment of the stock's actual current value, although we expect it to take six to 12 months for the market price to reflect this. When the target price is more than 20% above the current share price, the stock will be classified as a Buy; when it is between 5% and 20% above the current share price, the stock may be classified as a Buy or a Hold; when it is between 5% below and 5% above the current share price, the stock will be classified as a Hold; when it is between 5% and 20% below the current share price, the stock may be classified as a Hold or a Reduce; and when it is more than 20% below the current share price, the stock will be classified as a Reduce.

Our ratings are re-calibrated against these bands at the time of any 'material change' (initiation or resumption of coverage, change in target price or estimates).

Upside/Downside is the percentage difference between the target price and the share price.

Rating distribution for long-term investment opportunities

As of 30 September 2026, the distribution of all independent ratings published by HSBC is as follows:


Buy	60%	(12% of these provided with Investment Banking Services in the past 12 months)
Hold	35%	(12% of these provided with Investment Banking Services in the past 12 months)
Sell	4%	(10% of these provided with Investment Banking Services in the past 12 months)

For the purposes of the distribution above the following mapping structure is used under our current model Buy = Buy, Hold = Hold and Reduce = Sell. For rating definitions please see "Stock ratings and basis for financial analysis" above.

For the distribution of non-independent ratings published by HSBC, please see the disclosure page available at *http://www.hsbcnet.com/gbm/financial-regulation/investment-recommendations-disclosures*.

To view a list of all the independent fundamental ratings/recommendations disseminated by HSBC during the period, and the location where we publish our quarterly distribution of non-fundamental recommendations Income and Currencies research only), please use the following links to access the disclosure page:

Clients of HSBC Private Bank: *www.research.privatebank.hsbc.com/Disclosures*



All other clients: *www.research.hsbc.com/A/Disclosures*

HSBC & Analyst disclosures

Disclosure checklist

Company	Ticker	Recent price	Price date	Disclosure
BANK OF CHENGDU	601838.SS	18.89	21 Oct 2026	–
GUANGDONG EXPRESSWAY	000429.SZ	13.26	21 Oct 2026	–
HANSOH PHARMA	3692.HK	34.38	20 Oct 2026	–
KINGDEE	0268.HK	8.94	20 Oct 2026	7, 11
MIDEA GROUP	0300.HK	93.55	20 Oct 2026	4, 7
MIDEA GROUP A	000333.SZ	83.86	21 Oct 2026	4, 7
NARI TECHNOLOGY CO LTD	600406.SS	22.74	21 Oct 2026	7
NAURA TECHNOLOGY	002371.SZ	560.99	21 Oct 2026	–
SHENGYI TECHNOLOGY	600183.SS	118.99	21 Oct 2026	7
SIEYUAN ELECTRIC	002028.SZ	110.81	21 Oct 2026	7
WUXI BIOLOGICS	2269.HK	50.05	20 Oct 2026	4, 6, 7, 11

Source: HSBC

1 HSBC has managed or co-managed a public offering of securities for this company within the past 12 months.

2 HSBC expects to receive or intends to seek compensation for investment banking services from this company in the next 3 months.

3 At the time of publication of this report, HSBC Securities (USA) Inc. is a Market Maker in securities issued by this company.

4 As of 30 September 2026, HSBC beneficially owned 1% or more of a class of common equity securities of this company.

5 This company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of investment banking services.

6 This company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-investment banking securities-related services.

7 This company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-securities services.

8 A covering analyst/s has received compensation from this company in the past 12 months.

9 A covering analyst/s or a member of his/her household has a financial interest in the securities of this company, as detailed below.

10 A covering analyst/s or a member of his/her household is an officer, director or supervisory board member of this company, as detailed below.

11 At the time of publication of this report, HSBC is a non-US Market Maker in securities issued by this company and/or in securities in respect of this company.

12 As of 14 October 2026, HSBC beneficially held a net long position of more than 0.5% of this company's total issued share capital, calculated according to the SSR methodology.

13 As of 14 October 2026, HSBC beneficially held a net short position of more than 0.5% of this company's total issued share capital, calculated according to the SSR methodology.

14 HSBC Qianhai Securities Limited holds 1% or more of a class of common equity securities of this company.

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments, both equity and debt (including derivatives) of companies covered in HSBC Research on a principal or agency basis or act as a market maker or liquidity provider in the securities/instruments mentioned in this report.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking, sales & trading, and principal trading revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

Non-U.S. analysts may not be associated persons of HSBC Securities (USA) Inc, and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with the subject company, public appearances and trading securities held by the analysts.

Economic sanctions laws imposed by certain jurisdictions such as the US, the EU, the UK, and others, may prohibit persons subject to those laws from making certain types of investments, including by transacting or dealing in securities of particular issuers, sectors, or regions. This report does not constitute advice in relation to any such laws and should not be construed as an inducement to transact in securities in breach of such laws.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at *www.hsbcnet.com/research*. HSBC Private Bank clients should contact their Relationship Manager for queries regarding other research reports. In order to find out more about the proprietary models used to produce this report, please contact the authoring analyst.

HSBC may use Artificial Intelligence (AI) tools approved for adoption within HSBC in the development of its research reports, utilizing these technologies to analyse large volumes of data, enhance efficiency and improve the overall user experience. This includes but is not limited to paraphrasing, developing suitable captions and supporting data visualisation. It is important to note that while AI tools assist in various aspects of report creation, all investment recommendations and opinions presented herein are formulated and approved exclusively by our research analysts. The final content of the report reflects the professional judgement and expertise of our research analysts, ensuring compliance with regulatory standards and maintaining the integrity of our research process.

Additional disclosures

1 This report is dated as at 21 October 2026.

2 All market data included in this report are dated as at close 16 October 2026, unless a different date and/or a specific time of day is indicated in the report.

3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.

4 You are not permitted to use, for reference, any data in this document for the purpose of (i) determining the interest payable, or other sums due, under loan agreements or under other financial contracts or instruments, (ii) determining the price at which a financial instrument may be bought or sold or traded or redeemed, or the value of a financial instrument, and/or (iii) measuring the performance of a financial instrument or of an investment fund.

5 This report may be a translation of a report authored in another language. If so, and if there is any discrepancy between versions, the original-language version shall prevail.

Production & distribution disclosures

1. This report was produced and signed off by the author on 21 Oct 2026 08:43 GMT.

2. In order to see when this report was first disseminated please see the disclosure page available at https://research.hsbcqh.com.cn/R/34/stbW2jl

Disclaimer

Legal entities as at 13 May 2026:

HSBC Bank plc; HSBC Continental Europe; HSBC Continental Europe SA, Germany; HSBC Bank Middle East Limited, DIFC; HSBC Bank Middle East Limited, Dubai branch; HSBC Yatirim Menkul Degerler AS, Istanbul; The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch; HSBC Qianhai Securities Limited; HSBC Securities (Taiwan) Corporation Limited; HSBC Securities and Capital Markets (India) Private Limited, Mumbai; HSBC Bank Australia Limited; HSBC Securities (USA) Inc., New York; HSBC México, SA, Institución de Banca Múltiple, Grupo Financiero HSBC; Banco HSBC SA

Issuer of report
HSBC Qianhai Securities Limited
Unit 2201, 22/F, Qianhai Chow Tai Fook Finance Tower (Phase I), No. 66 Shu Niu Avenue, Nanshan Subdistrict, the Shenzhen Qianhai Shenzhen-Hong Kong Cooperation Zone, the PRC
Phone number: +86 755 8898 3288
Website: www.hsbcqh.com.cn

In mainland China, this document is issued and approved by HSBC Qianhai Securities Limited for the information of its clients only; it is not intended for and should not be distributed to retail customers in mainland China. HSBC Qianhai Securities Limited is regulated by the China Securities Regulatory Commission ("CSRC") and is qualified to engage in Securities Investment Advisory Business in mainland China [1B]. All inquiries by recipients must be directed to the HSBC Qianhai Securities Limited contact in mainland China. If it is received by a customer of an affiliate of HSBC Qianhai Securities Limited, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. This document is being supplied to you solely for your information and may not be redistributed or passed on, directly or indirectly, to any other person, in whole or in part, for any purpose. This document is not and should not be construed as an offer to sell or solicitation of an offer to purchase or subscribe for any investment. HSBC Qianhai Securities Limited has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC Qianhai Securities Limited makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. The decision and responsibility on whether or not to purchase, subscribe or sell (as applicable) must be taken by the investor. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient. Any form of written or verbal commitment on the sharing of gains or losses from the securities investment between the investors and the HSBC Qianhai Securities Limited arising from the research services provided are not permitted and shall be invalid. Expressions of opinion are those of the Research Division of HSBC Qianhai Securities Limited only and are subject to change without notice. From time to time research analysts conduct site visits of covered issuers. HSBC Qianhai Securities Limited and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment) to the extent permitted by law. HSBC policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits. HSBC Qianhai Securities Limited and its affiliates may act as market maker or have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or underwriting services for or relating to those companies and may also be represented on the supervisory board or any other committee of those companies. This document may contain hyperlinks to external websites for convenience of its recipients. HSBC Qianhai Securities Limited are not responsible for any content therein.

The Hongkong and Shanghai Banking Corporation Limited owns 90% and Qianhai Financial Holdings Co., Ltd. ("QFH") owns 10% of shares in HSBC Qianhai Securities Limited, which prepared and/or contributed to this research report. HSBC Qianhai Securities Limited has established policies and procedures reasonably designed to prevent QFH from exercising direct or indirect influence over the content of HSBC Qianhai Securities Limited research reports and the choice of companies that will be the subject of research reports. Furthermore, HSBC Qianhai Securities Limited has established additional policies and procedures reasonably designed to prevent any person or entity, whether from within HSBC Qianhai Securities Limited, QFH or otherwise, from influencing the activities of the HSBC Qianhai Securities Limited's research analysts or the content of research reports.

In Hong Kong, this document has been distributed by The Hongkong and Shanghai Banking Corporation Limited in the conduct of its Hong Kong regulated business for the information of its institutional and professional customers; it is not intended for and should not be distributed to retail customers in Hong Kong, unless permitted otherwise. The Hongkong and Shanghai Banking Corporation Limited makes no representations that the products or services mentioned in this document are available to persons in Hong Kong. Any enquiries with respect to any matters arising from, or in connection with, this research report should be directed to the recipient's contact person at The Hongkong and Shanghai Banking Corporation Limited. The analyst(s) named in this research report who is(are) not employed by and/or accredited to The Hongkong and Shanghai Banking Corporation Limited is(are) not licensed to carry on any regulated activities in Hong Kong under the SFO. The analyst(s) is(are) only named in this research report as being a source of the information contained herein and does(do) not purport to carry on any regulated activities in Hong Kong under the SFO or hold himself/herself(themselves) out as being able to do so. The document is intended to be distributed in its entirety. Unless governing law permits otherwise, you must contact a HSBC Group member in your home jurisdiction if you wish to use HSBC Group services in effecting a transaction in any investment mentioned in this document.

In the UK, this publication is distributed by HSBC Bank plc for the information of its Clients (as defined in the Rules of FCA) and those of its affiliates only. Nothing herein excludes or restricts any duty or liability to a customer which HSBC Bank plc has under the Financial Services and Markets Act 2000 or under the Rules of FCA and PRA. A recipient who chooses to deal with any person who is not a representative of HSBC Bank plc in the UK will not enjoy the protections afforded by the UK regulatory regime. HSBC Bank plc is regulated by the Financial Conduct Authority and the Prudential Regulation Authority.

In the European Economic Area, this publication has been distributed by HSBC Continental Europe or by such other HSBC affiliate from which the recipient receives relevant services.

In Japan, this publication has been distributed by HSBC Securities (Japan) Co., Ltd.. It may not be further distributed in whole or in part for any purpose. In Korea, this publication is distributed by either The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch ("HBAP SLS") or The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch ("HBAP SEL") for the general information of professional investors specified in Article 9 of the Financial Investment Services and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in whole or in part for any purpose. Both HBAP SLS and HBAP SEL are regulated by the Financial Services Commission and the Financial Supervisory Service of Korea. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act 2001 of Singapore ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. Only Economics or Currencies reports are intended for distribution to a person who is not an Accredited Investor, Expert Investor or Institutional Investor as defined in SFA. The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch accepts legal responsibility for the contents of reports. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. Recipients in Singapore should contact a "Hongkong and Shanghai Banking Corporation Limited, Singapore Branch" representative in respect of any matters arising from, or in connection with this report. Please refer to The Hongkong and Shanghai Banking Corporation Limited Singapore Branch's website at www.business.hsbc.com.sg for contact details. In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (ABN 48 006 434 162, AFSL No. 232595). These respective entities make no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient.

HSBC Securities (USA) Inc., a US-registered broker-dealer and member of FINRA, accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. The information contained herein is under no circumstances to be construed as investment advice and is not tailored to the needs of the recipient. All US persons receiving and/or accessing this report and wishing to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report. HSBC México, S.A., Institución de Banca Múltiple, Grupo Financiero HSBC is authorized and regulated by Secretaría de Hacienda y Crédito Público and Comisión Nacional Bancaria y de Valores (CNBV). In Brazil, this document has been distributed by Banco HSBC SA ("HSBC Brazil"), and/or its affiliates. As required by Resolution No. 20/2021 of the Securities and Exchange Commission of Brazil (Comissão de Valores Mobiliários), potential conflicts of interest concerning (i) HSBC Brazil and/or its affiliates; and (ii) the analyst(s) responsible for authoring this report are stated on the chart above labelled "HSBC & Analyst Disclosures".

If you are a customer of HSBC International Wealth & Premier Banking ("IWPB"), including HSBC Private Bank, you are eligible to receive this publication only if: (i) you have been approved to receive relevant research publications by an applicable HSBC legal entity; (ii) you have agreed to the applicable HSBC entity's terms and conditions and/or customer declaration for accessing research; and (iii) you have agreed to the terms and conditions of any other internet banking, online banking, mobile banking and/or investment services offered by that HSBC entity, through which you will access research publications (collectively with (ii), the "Terms"). If you do not meet the above eligibility requirements, please disregard this publication and, if you are a IWPB customer, please notify your Relationship Manager or call the relevant customer hotline. Distribution of this publication is the sole responsibility of the HSBC entity with whom you have agreed the Terms. Receipt of research publications is strictly subject to the Terms and any other conditions or disclaimers applicable to the provision of the publications that may be advised by IWPB.

Should you wish to use AI technology to help you analyse, summarise or evaluate this publication and/or any other research materials provided to you by HSBC, you shall seek prior written consent from HSBC Qianhai Securities Limited for any such use. Without obtaining a prior written consent from HSBC Qianhai Securities Limited, you shall not upload this publication and/or any other research materials produced by HSBC to an AI system or otherwise use AI technology in connection with the research services HSBC provides to you. For the purposes of this disclaimer, AI technology refers to any technology that uses computational, statistical, machine-learning, or other artificial intelligence techniques to infer or learn from data to find patterns, take actions, make decisions, or generate output.

© Copyright 2026, HSBC Qianhai Securities Limited, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of HSBC Qianhai Securities Limited.

[1291967]

HSBC Qianhai

HSBC Qianhai Research Team

Head of Research, HSBC Qianhai Securities
Steven Sun +86 755 8898 3158
stevensun@hsbcqh.com.cn

China Equity Strategy

Analyst, Head of China Equity Strategy Research
Steven Sun +86 755 8898 3158
stevensun@hsbcqh.com.cn

Analyst, China Equity Strategy Research
Jeffrey Xie +86 10 5795 2361
jeffrey.p.xie@hsbcqh.com.cn

Analyst, China Equity Strategy Research
Neal Chen +86 21 5066 2066
neal.m.chen@hsbcqh.com.cn

Analyst, China Equity Strategy Research
Lydia Li +86 21 5066 2022
lydia.j.y.li@hsbcqh.com.cn

Agriculture & Fishery

Analyst, Head of A-share Agriculture Research
Yihui Sha +86 21 5066 2004
yihui.sha@hsbcqh.com.cn

Auto & Auto Parts

Analyst, China Autos Research
Elaine Chen +86 10 5795 2364
elaine.chen@hsbcqh.com.cn

Analyst, China Autos Research
Michel Liu +86 10 5795 2351
michel.m.liu@hsbcqh.com.cn

Consumer

Analyst, Head of A-share Consumer Research
Kathy Song +86 21 5066 2007
kathy.l.h.song@hsbcqh.com.cn

Analyst, A-share Food & Beverage and Pulp & Paper Research
Darron Xue +86 755 8898 3407
darron.xue@hsbcqh.com.cn

Analyst, A-Share Consumer
Li Quan +86 755 8898 3471
li.quan@hsbcqh.com.cn

Analyst, A-Share Consumer
Doris Luo +86 755 8898 3161
doris.y.s.luo@hsbcqh.com.cn

Analyst, A-Share Consumer
Eric Liu +86 21 5066 2053
eric.x.c.liu@hsbcqh.com.cn

Financials

Analyst, Head of A-share Financials Research
Angel Sun +86 21 5066 2015
angel.y.sun@hsbcqh.com.cn

Industrials & Renewables

Analyst, Head of A-share Industrials & Renewables Research
Corey Chan +86 21 5066 2001
corey.chan@hsbcqh.com.cn

Analyst, A-share Industrials & Renewables Research
Amy Hu +86 755 8898 3408
ruo.lin.hu@hsbcqh.com.cn

Analyst, A-share Industrials & Renewables Research
Dun Wang +86 21 5066 2027
dun.wang@hsbcqh.com.cn

Analyst, A-share Industrials & Renewables Research
Echo Zhang +86 10 5795 2314
echo.x.zhang@hsbcqh.com.cn

Analyst, A-share Industrials & Renewables Research
Gary Yao +86 21 5066 2078
gary.x.d.yao@hsbcqh.com.cn

Healthcare

Analyst, Head of China Healthcare Research
Linda Shu +86 755 8898 3246
linda.y.l.shu@hsbcqh.com.cn

Analyst, China Healthcare Research
Cindy Chai +86 21 5066 2005
cindy.x.r.chai@hsbcqh.com.cn

Analyst, China Healthcare Research
Oliver Wang +86 21 5066 2058
oliver.h.y.wang@hsbcqh.com.cn

Analyst, China Healthcare Research
Andre Sun +86 21 5066 2034
andre.h.j.sun@hsbcqh.com.cn

Associate
Evie Liu

Petrochemical & New Materials

Analyst, Head of A-share Petrochem & New Materials Research
Yi Ru +86 21 5066 2008
yi.ru@hsbcqh.com.cn

Analyst, A-share Petrochem & New Materials Research
Jill Huang +86 21 5066 2024
jill.q.huang@hsbcqh.com.cn

Telecoms, Media & Technology

Analyst, A-share Technology Hardware Research
Bingyi Zheng +86 21 5066 2028
bingyi.zheng@hsbcqh.com.cn

Analyst, A-share Technology Hardware Research
Cara Su +86 21 5066 2080
cara.z.h.su@hsbcqh.com.cn

Associate
Yongzhu Wang

Analyst, Head of A-share Media & Internet Research
Jing Han +86 10 5795 2344
jing01.han@hsbcqh.com.cn

Analyst, A-share Media & Internet Research
Bruce Sun +86 10 5795 2357
bruce.z.j.sun@hsbcqh.com.cn

Analyst, Head of A-share IT Software Research
Yiran Liu +86 10 5795 2349
yiran1.liu@hsbcqh.com.cn

Analyst, A-share IT Software Research
Heng Zhang +86 10 5795 2384
heng.zhang@hsbcqh.com.cn

Transportation and Logistics

Analyst, Head of A-share Transportation & Logistics Research
David Wu +86 21 5066 2002
david.wu@hsbcqh.com.cn

Analyst, A-share Transportation & Logistics Research
William Sun +86 21 5066 2061
william.x.d.sun@hsbcqh.com.cn